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Summary Angiosarcomas are rare aggressive en-
dothelial tumours, and are associated with a poor
prognosis. Due to their vascular nature, there is
great interest in their response to anti-angiogenic
agents. A number of small prospective studies have
reported angiosarcoma response to vascular-targeted
agents, including agents that target vascular endothe-
lial growth factor. To date, the response to these
agents has been disappointing, and similar to the
response observed in other soft tissue sarcoma sub-
types. This short review will summarise the recent
data in this field.
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Introduction
Angiosarcomas are rare aggressive endothelial tu-
mours [1]. Angiosarcomas can occur spontaneously
or secondary to radiotherapy, chronic lymphoedema
and in a variety of familial conditions including neu-
rofibromatosis (NF-1), mutated breast cancer asso-
ciated gene 1 or 2 (BRCA1 or BRCA2) and Maffucci
syndrome. They can develop at any site, but most
commonly present as cutaneous disease, either as
primary tumours on the head and neck of elderly
white men, or on the chest wall secondary to breast
cancer treatment. Complete excision with wide mar-
gins is often technically challenging due to disease
extent and infiltration of surrounding tissue, effects
of previous surgery/radiotherapy on local anatomy
including lymphoedema, and co-morbidities in older
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patients. Angiosarcomas frequently recur despite
surgery. Doxorubicin or paclitaxel are chemothera-
pies recommended for the treatment of recurrent/
advanced disease. Evaluation of new agents has been
hampered by the rarity of angiosarcomas, but also by
the difficulty in assessing response in diffuse infiltrat-
ing tumours. Hence progression-free survival (PFS)
and overall survival (OS) are more robust endpoints
than response rate.
Over the past 20 years, the tumour vasculature has
become established as a target in the treatment of
cancer, particularly with agents that target vascular
endothelial growth factor (VEGF). As angiosarcomas
are endothelial tumours, there is interest in the re-
sponse of angiosarcoma to vascular-targeted agents.
This short review will summarise the recent data in
this field.
Paclitaxel
Paclitaxel is a microtubule-targeting chemotherapy
with anti-angiogenic activity [2]. Response to weekly
paclitaxel (80mg/m2) was assessed in a prospec-
tive single arm phase II study of 30 patients with
advanced angiosarcoma [3]; 36% of patients had re-
ceived previous chemotherapy. The response rate
(complete response [CR] + partial response [PR]) was
19%. Three patients with locally advanced disease had
tumour responses that enabled subsequent surgery,
and pathological CR were reported in 2 cases. The
median PFS was 4 months, and the median OS was
7.4 months. Angiosarcoma responses to doxorubicin
and paclitaxel have not been directly compared, but
these results are similar to those obtained with an-
thracycline-based chemotherapy in 108 angiosarcoma
patients prospectively enrolled in European Organ-
isation for the Research and Treatment of Cancer
(EORTC) trials, where the response rate was 25%,
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with median PFS and OS of 4.9 and 9.9 months re-
spectively, which were not significantly different to
those in other soft tissue sarcomas (STS) [4]. Weekly
paclitaxel is well tolerated and is often favoured as
first-line therapy, particularly for the treatment of
cutaneous angiosarcoma and in elderly patients.
Agents targeting VEGF
Bevacizumab
Bevacizumab is a humanised monoclonal antibody
to VEGF-A. Angiosarcoma response to bevacizumab
monotherapy (15mg/kg 3 weekly) was studied in
a single arm phase II study, which also recruited pa-
tients with epithelioid haemangioendothelioma [5].
In all, 23 patients with advanced angiosarcoma were
recruited, and in these patients, the response rate was
9% (2/23); 43% (10/23) of patients progressed within
6 weeks, and the median PFS was 3 months.
The addition of bevacizumab (10mg/kg 2 weekly)
to weekly paclitaxel (90mg/m2) was studied in a non-
comparative, open-label, randomised phase II study
[6]. The response rate was lower with combination
therapy (29% [7/25] vs 46% [11/24]), but the 6 month
PFS rate was identical. Furthermore, the addition
of bevacizumab to paclitaxel was associated with
higher rates of serious toxicity (44% vs 22%), and
more patients receiving combination treatment re-
quired dose reductions (56% vs 35%). The addition
of bevacizumab to weekly paclitaxel is therefore not
recommended.
Oral tyrosine kinase inhibitors
Angiosarcoma response to oral tyrosine kinase in-
hibitors that target VEGF receptors (VEGFR) has been
studied in several phase II studies.
Tumour response to sorafenib (a VEGFR, Raf-1, and
B-Raf inhibitor) 400 mg bis die (bd) was reported in
a study of 122 advanced sarcoma patients stratified by
histological subtype [7]. One CR and 4 PR were ob-
served in 34 patients with angiosarcoma. The median
PFS of the vascular sarcoma cohort, which included
2 patients with solitary fibrous tumour and 1 patient
with giant haemangioma, was 3.8 months. In com-
parison, the median PFS across all sarcoma subtypes
was 3.2 months. Angiosarcoma response to sorafenib
400mg bd was studied by the French Sarcoma Group
in two patient cohorts: 26 patients with cutaneous an-
giosarcoma and 15 patients with visceral disease [8].
The primary endpoint for this study was the 9-month
progression-free rate. Only 2 patients, 1 from each
cohort, were progression free at 9 months. The me-
dian PFS was 1.8 and 3.8 months for cutaneous and
visceral disease respectively.
STS response to pazopanib (a VEGFR, fibroblast
growth factor receptor [FGFR] and platelet derived
growth factor receptor [PDGFR] inhibitor) 800 mg
omni die (od) was studied in the phase II EORTC
62043 [9], and subsequent randomised placebo-con-
trolled phase III EORTC 62072 (PALETTE) study [10].
The median PFS of patients that received pazopanib
in the PALETTE study was 4.6 months, compared to
1.6 months in patients that received placebo (HR 0.31,
95% CI 0.24–0.40; p < 0.0001). Angiosarcoma response
to pazopanib was not reported separately; however
a retrospective analysis of a cohort of 40 angiosar-
coma patients treated with pazopanib in either the
EORTC 62043 study, the PALETTE study, or in routine
clinical practice, reported a 20% response rate and
median PFS of 3.0 months [11]. There were no signifi-
cant differences observed between different subtypes
of angiosarcoma in response to pazopanib.
Angiosarcoma response to axitinib (a VEGFR,
PDGFR and KIT inhibitor) 5 mg bd was recently
studied within a UK histologically stratified phase II
study (NCT01140737), which also included cohorts
for patients with advanced leiomyosarcoma, synovial
sarcoma and ‘other’ STS histologies. Preliminary re-
sults from the angiosarcoma cohort were reported at
the Connective Tissue Oncology Society 2016 annual
meeting; the response rate was 10%, 12 week non-
progression rate 42%, and median PFS 4.2 months
[12].
Agents targeting non-VEGF angiogenic pathways
Angiopoietin 1/2
Angiosarcoma response to weekly trebananib
(30mg/kg), an angiopoietin-1 and -2 peptibody, was
studied in a small single arm phase II study. No
responses were observed and the median PFS was
1.6 months. STS response to regorafenib 160mg od,
a multi-kinase inhibitor targeting VEGFR, PDGFR,
Kit, RET and Raf-1, as well as TIE2, an angiopoietin
receptor, was studied in a histologically stratified,
randomised, placebo-controlled phase II study [13].
Similar to STS response to pazopanib, an unplanned
pooled analysis of non-adipocytic STS cohorts re-
ported a median PFS 4.0 months with regorafenib
compared to 1.0 months with placebo (HR 0.36, 95%
CI 0.25–0.53; p < 0.0001). Angiosarcoma response to
regorafenib was not reported, but a separate study of
regorafenib for advanced angiosarcoma is currently
ongoing (NCT02048722).
PDGF
In addition to VEGFR, pazopanib, regorafenib and axi-
tinib also inhibit PDGFR. Olaratumab is a humanised
monoclonal antibody to PDGFa. Promising results
were observed in a randomised phase I/II study of
olaratumab in combination with doxorubicin as first-
line treatment for advanced STS [14]; a phase III study
recently completed recruitment and results are ea-
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gerly awaited (NCT 02451943). Angiosarcoma re-
sponse to olaratumab has not been reported.
Endoglin
The transforming growth factor (TGF)-β and bone
morphogenetic protein (BMP)-9 receptors activin
receptor-line kinase (ALK)-1 and endoglin are re-
quired for normal vascular development, and are
highly expressed on tumour endothelial cells [15].
TRC105 is a chimeric monoclonal antibody that
binds endoglin [16]. Non-adipocytic STS response
to TRC105 in combination with pazopanib was stud-
ied in a phase I/II study [17]; response to treatment
was observed in 8/9 angiosarcoma patients, including
two durable CR. A randomised phase III trial of pa-
zopanib ± TRC105 in angiosarcoma recently opened
to recruitment (NCT02979899).
Other vascular targeted agents
Thalidomide
Angiosarcoma response to thalidomide, an immuno-
modulatory agent with anti-angiogenic properties
[18], has been described in several case reports
[19, 20], however response has not been studied
in a prospective trial.
Metronomic chemotherapy
Metronomic chemotherapy is the concept of admin-
istering chemotherapy drugs in frequent, often daily,
low doses. It reduces tumour micro-vessel density,
tumour hypoxia, and improves tumour perfusion,
consistent with a vascular-targeted response [21]. An-
giosarcoma response to metronomic chemotherapy
has been reported in a few case studies [22]. A ret-
rospective series of 26 elderly patients with advanced
STS treated with metronomic oral cyclophosphamide
100mg bd, which included 3 patients with angiosar-
coma, reported a disease control rate of 69% and
a median PFS of 6.8 months [23].
Beta-blockers
The beta-blocker propranolol is recommended for
the treatment of complex infantile haemangiomas
[24]. Interestingly, beta-adrenergic receptors have
also been identified as a potential therapeutic target
in malignant vascular tumours [25]. A case series of
7 patients with advanced angiosarcoma treated with
oral propranolol 40mg bd in combination with weekly
metronomic vinblastine (6mg/m2) plus methotrexate
(35mg/m2) reported a 100% response rate and a me-
dian PFS of 11 months [26].
Discussion
Despite their vascular nature, angiosarcoma response
to VEGF-targeted agents is limited, and similar to
the response observed in other more common STS
subtypes. Biomarkers are required to identify patients
most likely to respond to treatment. In a small cohort
study, activating VEGFR2 mutations were identified in
14% (3/22) of angiosarcoma tumour samples [27]. No
VEGFR2 mutations were identified in 27 tumour sam-
ples available for analysis from the French Sarcoma
Group study of sorafenib for advanced angiosarcoma
[8]. In a separate study, mutations in angiogenesis-
related genes were identified in 38% (15/39) of an-
giosarcoma tumour samples [28], including recurrent
mutations in vascular endothelial-phosphotyrosine
phosphatase (VE-PTP) and phospholipase gamma 1
(PLCG1). The response of angiosarcomas harbouring
mutations in angiogenesis-related genes to vascular
targeted agents has not been correlated.
Angiosarcoma tumour cells express multiple angio-
genic growth factors [29]. Angiosarcoma expression
of these factors is associated with improved patient
outcomes [30], and thus expression may be a mea-
sure of tumour endothelial differentiation rather than
a pathological driver of disease. Furthermore, the ex-
pression of multiple angiogenic growth factors rep-
resents potential resistance mechanisms to targeted
agents. Despite the negative results of paclitaxel in
combination with bevacizumab [6], further combina-
tion studies—either anti-angiogenic agents in combi-
nation with chemotherapy or combinations of differ-
ent anti-angiogenic agents—are indicated.
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